Clarkston Capital Partners’s Charles River Laboratories CRL Stock Holding History

Clarkston Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-143,433	Closed	-$9.11M	–	132
2015 Q3	$9.11M	Buy	143,433 +1,820	+1%	+$131K	0.83%	45
2015 Q2	$9.96M	Buy	141,613 +19,441	+16%	+$1.44M	1.02%	42
2015 Q1	$9.69M	Buy	122,172 +13,487	+12%	+$995K	1.07%	37
2014 Q4	$6.92M	Buy	108,685 +2,025	+2%	+$127K	1.05%	32
2014 Q3	$6.37M	Buy	106,660 +6,565	+7%	+$376K	1.1%	30
2014 Q2	$5.36M	Sell	100,095 -1,890	-2%	-$104K	0.99%	34
2014 Q1	$6.15M	Buy	101,985 +45,635	+81%	+$2.66M	1.23%	28
2013 Q4	$2.99M	Buy	56,350 +15,125	+37%	+$760K	1.16%	29
2013 Q3	$1.91M	Buy	41,225 +8,220	+25%	+$377K	0.92%	36
2013 Q2	$1.35M	Buy	+33,005	New	+$1.41M	0.75%	41

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Clarkston Capital Partners's CRL Position: Q4 2015 in Review

Clarkston Capital Partners sold out of Charles River Laboratories (CRL) in Q4 2015, closing a stake of 143,433 shares — an estimated $9.11M sold.

Clarkston Capital Partners first reported a position in CRL in Q2 2013 and held it in 10 quarters. The position peaked at $9.96M in Q2 2015. 268 funds tracked by Wall St. Rank hold CRL as of Q4 2015.

Clarkston Capital Partners reported no remaining Charles River Laboratories position as of Q4 2015 after selling out during the quarter.
Clarkston Capital Partners sold 143,433 Charles River Laboratories shares in Q4 2015, an estimated $9.11M.
Clarkston Capital Partners first reported a position in Charles River Laboratories in Q2 2013 and held it in 10 quarters.
Clarkston Capital Partners's Charles River Laboratories position peaked at $9.96M in Q2 2015.
268 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2015.

Based on Clarkston Capital Partners's 13F filing for Q4 2015, filed 8 Feb 2016.